Moody Lynn & Lieberson’s AstraZeneca AZN Stock Holding History

Moody Lynn & Lieberson’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,732	Closed	-$4.48M	–	265
2026 Q1	$4.48M	Sell	22,732 -1,207	-5%	-$233K	0.25%	53
2025 Q4	$4.4M	Buy	23,939 +11,278	+89%	+$1.98M	0.23%	59
2025 Q3	$1.94M	Buy	+12,661	New	+$1.92M	0.1%	86
2024 Q3	–	Sell	-16,625	Closed	-$2.59M	–	256
2024 Q2	$2.59M	Buy	+16,625	New	+$2.5M	0.17%	75
2022 Q3	–	Sell	-42,594	Closed	-$5.63M	–	219
2022 Q2	$5.63M	Sell	42,594 -670	-2%	-$87.9K	0.51%	49
2022 Q1	$5.74M	Buy	43,264 +13,145	+44%	+$1.58M	0.42%	50
2021 Q4	$3.51M	Buy	+30,119	New	+$3.54M	0.24%	76

Other funds holding AZN

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

CDDEC

Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

ZIC

ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

Moody Lynn & Lieberson's AZN Position: Q2 2026 in Review

Moody Lynn & Lieberson sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 22,732 shares — an estimated $4.48M sold.

Moody Lynn & Lieberson first reported a position in AZN in Q4 2021 and held it in 7 quarters. The position peaked at $5.74M in Q1 2022. 443 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Moody Lynn & Lieberson reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Moody Lynn & Lieberson sold 22,732 AstraZeneca shares in Q2 2026, an estimated $4.48M.
Moody Lynn & Lieberson first reported a position in AstraZeneca in Q4 2021 and held it in 7 quarters.
Moody Lynn & Lieberson's AstraZeneca position peaked at $5.74M in Q1 2022.
443 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Moody Lynn & Lieberson's 13F filing for Q2 2026, filed 20 Jul 2026.